Evaluating the Toxicity Profile of Parsaclisib in Mantle Cell Lymphoma
Amitkumar Mehta, MD, discusses the toxicity profile of parsaclisib in the phase 2 CITADEL-205 clinical trial of relapsed/refractory mantle cell lymphoma.
Amitkumar Mehta, MD, an associate professor at the University of Alabama at Birmingham Comprehensive Cancer Center, discusses the toxicity profile of the first-in-class PI3Kδ inhibitor parsaclisib, according to findings from this agent in the phase 2 CITADEL-205 clinical trial (NCT03235544) of relapsed/refractory mantle cell lymphoma (MCL).
Parsaclisib is a highly specific PI3Kδ inhibitor compared with the other PI3Kδ inhibitors, and it was designed to reduce transaminitis as a side effect, says Mehta. This study aimed to explore the efficacy and safety of this therapy.
Overall, the occurrence of transaminitis was very low, especially in terms of grade 3/4 toxicity, which occurred in about 3% to 4%. Diarrhea was observed, which is a known class side effect, according to Mehta. Grade 3 or higher diarrhea occurred in about 13% of patients in the study, and for about half of the patients, this was reason for discontinuation.
Mehta says physicians have learned to be proactive about this side effect. If a patient has diarrhea, physicians should act quickly to manage it.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
